Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

DelveInsight's Biosensors Market Insights report provides the current and forecast market analysis, individual leading ...

Eli Lilly (NYSE:LLY) recently announced its plans to invest $27 billion in four new U.S. manufacturing plants over the next five years, creating thousands of jobs. This move comes at a time when ...

This streamlines workflows and makes sophisticated drug design tasks accessible to all researchers. AI makes software more intuitive. Chemists can use natural language to execute tasks ...

In October, Eli Lilly announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. Price Action: LLY stock is down 0.42% ...

In October, Eli Lilly announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. Price Action: LLY stock is down 0.42% at ...

(CNN) — Eli Lilly, the maker of blockbuster weight ... that Ricks called “sort of the next super weight-loss drug from Lilly.” Used by millions of Americans, approved medicines in the ...

Eli Lilly plans to invest $27 billion in four new pharmaceutical manufacturing facilities in the U.S., expanding its domestic production of medications across multiple therapeutic areas.

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...